Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
Leukemia, 2015 - nature.com
Philadelphia chromosome-positive (Ph+) leukemia is driven by the constitutive enzymatic
activity of the BCR-ABL1 fusion kinase. 1 Tyrosine kinase inhibitors (TKIs) that block the …
activity of the BCR-ABL1 fusion kinase. 1 Tyrosine kinase inhibitors (TKIs) that block the …
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.
MS Zabriskie, NA Vellore, KC Gantz, MW Deininger… - Leukemia, 2015 - europepmc.org
Philadelphia chromosome positive (Ph+) leukemia is driven by the constitutive enzymatic
activity of the BCR-ABL1 fusion kinase. 1 Tyrosine kinase inhibitors (TKIs) that block the …
activity of the BCR-ABL1 fusion kinase. 1 Tyrosine kinase inhibitors (TKIs) that block the …
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
MS Zabriskie, NA Vellore, KC Gantz, MW Deininger… - Leukemia, 2015 - go.gale.com
Philadelphia chromosome-positive (Ph+) leukemia is driven by the constitutive enzymatic
activity of the BCR-ABL1 fusion kinase. 1 Tyrosine kinase inhibitors (TKIs) that block the …
activity of the BCR-ABL1 fusion kinase. 1 Tyrosine kinase inhibitors (TKIs) that block the …
[HTML][HTML] Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1
MS Zabriskie, NA Vellore, KC Gantz, MW Deininger… - Leukemia, 2015 - ncbi.nlm.nih.gov
Philadelphia chromosome positive (Ph+) leukemia is driven by the constitutive enzymatic
activity of the BCR-ABL1 fusion kinase. 1 Tyrosine kinase inhibitors (TKIs) that block the …
activity of the BCR-ABL1 fusion kinase. 1 Tyrosine kinase inhibitors (TKIs) that block the …
[引用][C] Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
MS Zabriskie, NA Vellore, KC Gantz… - …, 2015 - pubmed.ncbi.nlm.nih.gov
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1 Radotinib is
an effective inhibitor of native and kinase domain-mutant BCR-ABL1 Leukemia. 2015 Sep;29(9):1939-42 …
an effective inhibitor of native and kinase domain-mutant BCR-ABL1 Leukemia. 2015 Sep;29(9):1939-42 …
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.
MS Zabriskie, NA Vellore, KC Gantz… - Leukemia …, 2015 - search.ebscohost.com
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1 Page 1
LETTERS TO THE EDITOR Radotinib is an effective inhibitor of native and kinase domain-mutant …
LETTERS TO THE EDITOR Radotinib is an effective inhibitor of native and kinase domain-mutant …
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
MS Zabriskie, NA Vellore, KC Gantz, MW Deininger… - Leukemia, 2015 - go.gale.com
Philadelphia chromosome-positive ([Ph. sup.+]) leukemia is driven by the constitutive
enzymatic activity of the BCR-ABL1 fusion kinase.(1) Tyrosine kinase inhibitors (TKIs) that …
enzymatic activity of the BCR-ABL1 fusion kinase.(1) Tyrosine kinase inhibitors (TKIs) that …
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.
MS Zabriskie, NA Vellore, KC Gantz, MW Deininger… - Leukemia, 2015 - europepmc.org
Philadelphia chromosome positive (Ph+) leukemia is driven by the constitutive enzymatic
activity of the BCR-ABL1 fusion kinase. 1 Tyrosine kinase inhibitors (TKIs) that block the …
activity of the BCR-ABL1 fusion kinase. 1 Tyrosine kinase inhibitors (TKIs) that block the …